Abstract: A positive electrode active material for a lithium secondary battery and a method for manufacturing the same are disclosed herein. In some embodiments, a positive electrode active material comprises a positive electrode active material powder and a coating layer on a surface of the positive electrode active material powder, where the coating layer comprising a lithium molybdenum compound. The positive electrode active material may improve output and stability in a lithium secondary battery.

Abstract: The present invention relates to a peptide analog or a pharmaceutically acceptable salt thereof with excellent moisturizing effect, and use thereof for moisturization. More specifically, the present invention relates to a novel peptide analog or a pharmaceutically acceptable salt thereof, a method for preparation thereof, a moisturizing cosmetic composition comprising the same as an active ingredient, and a pharmaceutical composition for prevention and treatment of xeroderma.

Abstract: The present invention relates to a biotin-conjugated hexapeptide-2 derivative or a pharmaceutically acceptable salt thereof and use thereof. More particularly, the present invention relates to a biotin-conjugated hexapeptide-2 derivative or a pharmaceutically acceptable salt thereof, a preparation method thereof, a composition including the same as an active ingredient, and a method for improving wrinkles and inhibiting skin aging using the same.

Abstract: A controlled-release composition and controlled-release microspheres containing an exendin as an active ingredient, and a method of preparing the same are provided. More specifically, a controlled-release composition containing an exendin as an active ingredient, a biodegradable polymer with a specific viscosity, and coating materials, having high bioavailability and showing sustained release of the active ingredient in an effective concentration for a certain period without an excessive initial burst of the active ingredient; controlled-release microspheres containing a core including an exendin as an active ingredient and a biodegradable polymer, and a coating layer coating the core; and a method of preparing controlled-release microspheres including the steps of mixing an exendin, a biodegradable polymer, and a solvent, removing the solvent from the mixture to prepare hardened microspheres, and coating the hardened microspheres to form a coating layer on the surface of each microsphere, are provided.

Abstract: The present invention relates to a biotin-conjugated hexapeptide-2 derivative or a pharmaceutically acceptable salt thereof and use thereof. More particularly, the present invention relates to a biotin-conjugated hexapeptide-2 derivative or a pharmaceutically acceptable salt thereof, a preparation method thereof, a composition including the same as an active ingredient, and a method for improving wrinkles and inhibiting skin aging using the same.

Abstract: The present invention relates to a stabilized vitamin C derivative with a peptide molecule linked to vitamin C or a pharmaceutically acceptable salt thereof, a method of preparing the same, and a composition containing the same.

Abstract: The present invention relates to a peptide analogue or a pharmaceutically acceptable salt thereof with excellent moisturizing effect, and use thereof for moisturization. More specifically, the present invention relates to a novel peptide analogue or a pharmaceutically acceptable salt thereof, a method for preparation thereof, a moisturizing cosmetic composition comprising the same as an active ingredient, and a pharmaceutical composition for prevention and treatment of xeroderma.

Abstract: The present invention relates to a stabilized vitamin C derivative with a peptide molecule linked to vitamin C or a pharmaceutically acceptable salt thereof, a method of preparing the same, and a composition containing the same.

Abstract: A controlled-release composition and controlled-release microspheres containing an exendin as an active ingredient, and a method of preparing the same are provided. More specifically, a controlled-release composition containing an exendin as an active ingredient, a biodegradable polymer with a specific viscosity, and coating materials, having high bioavailability and showing sustained release of the active ingredient in an effective concentration for a certain period without an excessive initial burst of the active ingredient; controlled-release microspheres containing a core including an exendin as an active ingredient and a biodegradable polymer, and a coating layer coating the core; and a method of preparing controlled-release microspheres including the steps of mixing an exendin, a biodegradable polymer, and a solvent, removing the solvent from the mixture to prepare hardened microspheres, and coating the hardened microspheres to form a coating layer on the surface of each microsphere, are provided.

Abstract: A mobile station adapted for channel switching comprises an input unit adapted to receive user input associated with selection of content. The mobile station also comprises a timer generating unit operatively coupled to the input unit, adapted to generate a timer related to transmission of a command derived from the user input to a content server in response to the user input. The mobile station also comprises a transmitting unit operatively coupled to the input unit, adapted to transmit the command derived from the user input to the content server in response to expiration of the timer. The mobile station also comprises a receiving unit operatively coupled to the transmitting unit, adapted to receive the content from the content server in response to receipt of the command derived from the user input by the content server.

Abstract: This invention relates to a technology of modifying low-molecular-weight bioactive substances with short in vivo half-life and low stability in order to achieve a stable and efficient in vivo delivery thereof. More specifically, the present invention relates to a stable bioactive substance-blood protein conjugate, wherein a low-molecular-weight bioactive substance is ex vivo conjugated with a specific functional group on a blood protein through a reactive group, the low-molecular-weight bioactive substance is available as a drug for treatment and prevention in mammals including human and selected from the group consisting of a natural substance; and a method of a stable and efficient in vivo delivery of the low-molecular-weight bioactive substance based on the use of the bioactive substance-blood protein conjugate.

Abstract: A mobile station adapted for channel switching comprises an input unit adapted to receive user input associated with selection of content. The mobile station also comprises a timer generating unit operatively coupled to the input unit, adapted to generate a timer related to transmission of a command derived from the user input to a content server in response to the user input. The mobile station also comprises a transmitting unit operatively coupled to the input unit, adapted to transmit the command derived from the user input to the content server in response to expiration of the timer. The mobile station also comprises a receiving unit operatively coupled to the transmitting unit, adapted to receive the content from the content server in response to receipt of the command derived from the user input by the content server.

Abstract: The present invention relates to a sustained release formulation comprising protein as an active ingredient, and a preparation method thereof. According to the present invention, the sustained release formulation contains protein drugs that are encapsulated in biodegradable hydrophobic matrices as pharmaceutically active forms by forming complexes with sulfated polysaccharides. The sustained release formulation prepared by the present invention can be used to effectively treat a disease without frequent injections by keeping the protein concentration at a sufficiently high level for a long period when injected in vivo once.